Rhythm Pharmaceuticals, Inc., a Delaware corporation, was founded in February 2013. The company is a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients and their families with rare neuroendocrine diseases. The company is focused on advancing melanocortin -4 receptor agonists, including their main asset, IMCIVREE, as a precision drug designed to treat hyperappetite and severe obesity caused by rare MC4R pathway diseases.
